Oxycodone hydrochloride
Brand names: OxyNorm, OxyContin, Shortec, Longtec
Oxycodone is a strong opioid for moderate-to-severe pain, including post-operative and cancer pain, available in immediate- and modified-release forms.
Adult dose
Paediatric dose
Dose adjustments
§4.2, Patients with renal or hepatic impairment, verbatim: 'The plasma concentration in this patient population may be increased. The dose initiation should follow a conservative approach in these patients. The recommended adult starting dose should be reduced by 50% (for example a total daily dose of 10 mg orally in opioid naïve patients), and each patient should be titrated to adequate pain control according to their clinical situation.' §4.4 additionally lists impaired renal function among the conditions in which 'Caution must be exercised'. No eGFR band or threshold appears anywhere in the fetched text.
The same §4.2 sentence applies: 'The recommended adult starting dose should be reduced by 50% (for example a total daily dose of 10 mg orally in opioid naïve patients), and each patient should be titrated to adequate pain control according to their clinical situation.' ⚠ But note the harder limit in §4.3: this SPC CONTRAINDICATES oxycodone in 'moderate to severe hepatic impairment', so the 50% reduction applies only to mild impairment. No Child-Pugh threshold is given.
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
US labelling (FDA)
Reference — US labelling, may differ from UKOxycodone hydrochloride tablets should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks. (2.1) Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals. Reserve titration to higher doses of oxycodone hydrochloride for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks. (2.1, 5) Many acute pain conditions (e.g., the pain that occurs with a number of surgical procedures or acute musculoskeletal injuries) require no more than a few days of an …
Source: US FDA prescribing information (openFDA / DailyMed), label dated 2026-01-14. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.
Contraindications
- Hypersensitivity to oxycodone or to any of the excipients listed in section 6.1
- Severe respiratory depression with hypoxia
- Paralytic ileus
- Acute abdomen
- Delayed gastric emptying
- Severe chronic obstructive lung disease
- Cor pulmonale
- Severe bronchial asthma
- Elevated carbon dioxide levels in the blood
- Moderate to severe hepatic impairment
- Chronic constipation
Side effects
- Very common: somnolence, dizziness, headache
- Very common: constipation, nausea, vomiting
- Very common: pruritus
- Common: anxiety, confusional state, depression, insomnia, nervousness, abnormal thinking, abnormal dreams
- Common: tremor, lethargy, sedation
- Common: dyspnoea, bronchospasm, cough decreased
- Common: abdominal pain, diarrhoea, dry mouth, dyspepsia
- Common: decreased appetite
- Common: rash, hyperhidrosis
- Common: asthenia, fatigue
- Uncommon: respiratory depression, hiccups
- Uncommon: hypersensitivity; dehydration
- Uncommon: agitation, affect lability, euphoric mood, hallucinations, decreased libido, disorientation, mood altered, restlessness, dysphoria
- Uncommon: amnesia, convulsion, hypertonia, hypoaesthesia, involuntary muscle contractions, speech disorder, syncope, paraesthesia, dysgeusia, hypotonia
- Uncommon: visual impairment, miosis; vertigo
- Uncommon: palpitations (in the context of withdrawal syndrome), supraventricular tachycardia; vasodilatation, facial flushing
- Uncommon: dysphagia, flatulence, eructation, ileus, gastritis
- Uncommon: increased hepatic enzymes, biliary colic
- Uncommon: dry skin, exfoliative dermatitis
- Uncommon: urinary retention, ureteral spasm
- Uncommon: erectile dysfunction, hypogonadism
- Uncommon: malaise, oedema, peripheral oedema, thirst, pyrexia, chills
- Rare: hypotension, orthostatic hypotension; urticaria
- Frequency not known: anaphylactic and anaphylactoid reaction; aggression; drug dependence; hyperalgesia; central sleep apnoea syndrome; dental caries; cholestasis; amenorrhoea; neonatal drug withdrawal syndrome; opioid tolerance; opioid withdrawal syndrome
- §4.8 is truncated at the source-fetch limit, so this list may be incomplete
Monitoring
- Respiratory depression — §4.4, verbatim: 'The primary risk of opioid excess is respiratory depression'
- If co-prescribed with benzodiazepines or related sedatives: 'The patient should be followed closely for signs and symptoms of respiratory depression and sedation', and inform patients and carers to watch for these symptoms
- Sleep-related breathing disorders — opioids increase the risk of central sleep apnoea in a dose-dependent fashion; 'In patients who present with CSA, consider decreasing the total opioid dosage'
- Bowel function — discontinue immediately if paralytic ileus is suspected or occurs; after abdominal surgery do not use 'until the physician is assured of normal bowel function'
- Tolerance, dependence, addiction and withdrawal — agree a plan for ending treatment before starting, keep 'frequent contact between the physician and the patient to evaluate the need for continued treatment', and taper rather than stop abruptly
- Reassess pain control regularly — 'In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered'
- Constipation and nausea: 'Constipation may be prevented with an appropriate laxative. If nausea and vomiting are troublesome, oxycodone may be combined with an anti-emetic'
Clinical monograph
How it works
It is an agonist at opioid receptors (mainly mu), reducing pain perception and transmission.
Prescribing in practice
- Start low — especially in older patients and renal or hepatic impairment — and co-prescribe a regular laxative; use equivalence tables when switching opioids.
- It is a controlled drug with dependence and diversion potential; additive respiratory depression with other CNS depressants.
- Immediate-release and modified-release forms are not interchangeable dose-for-dose, and modified-release tablets must not be crushed.
Monitoring
Review pain relief, sedation, bowel habit and signs of dependence; reassess the ongoing need and ensure naloxone access where overdose risk is high.
Counselling the patient
- It commonly causes constipation — take the laxative provided.
- Do not combine it with alcohol or other sedatives.
- Take it exactly as prescribed; it can be habit-forming, and do not crush modified-release tablets.
Evidence & guidelines
A strong opioid for moderate-to-severe pain, used within opioid-stewardship principles with laxative co-prescription.
Reference: NICE CG140; UK FPM; Palliative care formulary; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Morphine Milligram Equivalents (MME) Calculator · Pain / Opioids
- Opioid Conversion / Equianalgesic Guide · Pain Management
- Numeric Rating Scale (NRS) Pain Assessment and Management · Pain Management
- Finnegan Neonatal Abstinence Scoring Tool (FNAST) · Neonatal Abstinence Syndrome
- Modified Finnegan Neonatal Abstinence Score (NAS) · Neonatal
- Withdrawal Assessment Tool (WAT-1) for Paediatric Iatrogenic Withdrawal · Critical Care
- Difficult Airway Algorithm (DAS) · DAS 2015; Royal College of Anaesthetists
- Major Haemorrhage Protocol · NICE NG24; UK MHP guidelines
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines